Recent Finacing
Recent Raise
Engrail Therapeutics is a clinical-stage neuroscience company that acquires, develops, and commercializes subtype-selective GABAA modulators (ENX-101, ENX-102) via licensing, co-development, and acquisitions for neuropsychiatric disorders.
